RT Journal Article
SR Electronic
T1 Statins Are Associated with Improved 28-day Mortality in Patients Hospitalized with SARS-CoV-2 Infection
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.03.27.21254373
DO 10.1101/2021.03.27.21254373
A1 Memel, Zoe N.
A1 Lee, Jenny J.
A1 Foulkes, Andrea S.
A1 Chung, Raymond T.
A1 Thaweethai, Tanayott
A1 Bloom, Patricia P.
YR 2021
UL http://medrxiv.org/content/early/2021/04/06/2021.03.27.21254373.abstract
AB Background Statins may be protective in viral infection and have been proposed as treatment in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection.Objective We evaluated the effect of statins on mortality in four groups hospitalized with (SARS-CoV-2) infection (continued statin, newly initiated statin, discontinued statin, never on statin).Design In a single center cohort study of 1179 patients hospitalized with SARS-CoV-2 infection, the outcome of death, Intensive Care Unit (ICU) admission or hospital discharge was evaluated. Patients’ statin use, laboratory data, and co-morbidities were determined via chart review and electronic health records. Using marginal structural models to account for timing of statin initiation and competing risks, we compared the likelihood of severe outcomes in the four statin exposure groups.Setting Academic medical center in the United StatesParticipants Patients hospitalized with SARS-CoV-2 infectionMeasurements 28-day mortality, ICU admission, or dischargeResults Among 1179 patients, 360 were never on a statin, 311 were newly initiated on a statin, 466 were continued on a statin, and 42 had a statin discontinued. In this cohort, 154 (13.1%) patients died by 28-days. With marginal structural model analysis, statin use reduced the hazard of 28-day mortality (HR 0.566 [CI 0.372, 0.862], p = 0.008). Both new initiation of statins (HR 0.493 [CI 0.253, 0.963], p=0.038) and continuing statin therapy reduced the hazard of 28-day mortality (HR 0.270 [CI 0.114, 0.637], p=0.003). Sensitivity analysis found that statin use was associated with improved mortality for patients > 65 years, but not for patients 65 years or younger.Limitation Observational designConclusion Statin therapy during hospitalization for SARS-CoV-2 infection, including new initiation and continuation of therapy, was associated with reduced short-term mortality.Competing Interest StatementThe authors have declared no competing interest.Funding StatementSupport for this study was provided by the MGH Division of Clinical Research. Funding was used primarily to support the MGH COVID-19 registry development. Several of the authors individually have received research grants that are specified in the disclosures section of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the MGH Institutional Review Board (IRB # 2020P000829); a waiver of informed consent was granted.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThis data was obtained from the MGH Covid-19 Data registry. Readers can contact the corresponding author for further information.SARS-CoV-2Severe Acute Respiratory Syndrome Coronavirus 2COVID-19Coronavirus disease 2019MGHMassachusetts General HospitalACE-2Angiotensin-converting enzyme-2ASTAspartate Aminotransferase testALTAlanine Aminotransferase testICUIntensive Care UnitHRHazard RatioCIConfidence IntervalARDSacute respiratory distress syndromeEDWEnterprise Data WarehouseBMIBody Mass IndexWBCwhite blood cell countCRPC-reactive proteinHIVHuman Immunodeficiency VirusCOPDChronic Obstructive Pulmonary DiseaseILDInterstitial Lung DiseaseIQRInterquartile rangeNAFLDNon-alcoholic Fatty Liver DiseaseALCAbsolute lymphocyte countCKCreatine Kinase